Elanco Animal Health Incorporated Investing Cash Flow
Elanco Animal Health Incorporated (ELAN) reported Investing Cash Flow of -$170.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$110.00M.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$60.00M.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$64.00M.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$101.00M, a 108.12% decline year-over-year.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for fiscal 2025 was -$279.00M, a 124.09% decline from fiscal 2024.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for fiscal 2024 was $1.16B.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for fiscal 2023 was -$169.00M.
- Elanco Animal Health Incorporated net cash provided by (used in) investing activities for fiscal 2022 was -$179.00M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 9 month as first filed | Net Cash Provided by (Used in) Investing Activities 12 month | Net Cash Provided by (Used in) Investing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$110.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$170.00M 10-Q · filed 2026-08-05 | -$234.00M derived: sum of 3 quarters · filed 2026-08-05 | -$335.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$60.00M 10-Q · filed 2026-05-06 | -$124.00M derived: sum of 2 quarters · filed 2026-05-06 | -$225.00M derived: sum of 3 quarters · filed 2026-05-06 | -$281.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | -$64.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$165.00M derived: sum of 2 quarters · filed 2026-02-24 | -$221.00M derived: sum of 3 quarters · filed 2026-08-05 | -$279.00M 10-K · filed 2026-02-24 | |||
| 2025-09-30 | -$101.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$157.00M derived: sum of 2 quarters · filed 2026-08-05 | -$215.00M 10-Q · filed 2025-11-05 | -$305.00M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | -$56.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$114.00M 10-Q · filed 2026-08-05 | -$204.00M derived: sum of 3 quarters · filed 2026-08-05 | $1.04B derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | -$58.00M 10-Q · filed 2026-05-06 | -$148.00M derived: sum of 2 quarters · filed 2026-05-06 | $1.10B derived: sum of 3 quarters · filed 2026-05-06 | $1.06B derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$90.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.15B derived: sum of 2 quarters · filed 2026-02-24 | $1.12B derived: sum of 3 quarters · filed 2026-02-24 | $1.16B 10-K · filed 2026-02-24 | |||
| 2024-09-30 | $1.24B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.21B derived: sum of 2 quarters · filed 2025-11-05 | $1.25B 10-Q · filed 2025-11-05 | $1.21B derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-06-30 | -$33.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $4.00M 10-Q · filed 2025-08-07 | -$31.00M derived: sum of 3 quarters · filed 2026-02-24 | -$67.00M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2024-03-31 | $37.00M 10-Q · filed 2025-05-07 | $2.00M derived: sum of 2 quarters · filed 2026-02-24 | -$34.00M derived: sum of 3 quarters · filed 2026-02-24 | -$77.00M derived: sum of 4 quarters · filed 2026-02-24 | |||
| 2023-12-31 | -$35.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$71.00M derived: sum of 2 quarters · filed 2026-02-24 | -$114.00M derived: sum of 3 quarters · filed 2026-02-24 | -$169.00M 10-K · filed 2026-02-24 | |||
| 2023-09-30 | -$36.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$79.00M derived: sum of 2 quarters · filed 2024-11-07 | -$134.00M 10-Q · filed 2024-11-07 | -$210.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | -$43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$98.00M 10-Q · filed 2024-08-08 | -$174.00M derived: sum of 3 quarters · filed 2025-02-25 | -$211.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | -$55.00M 10-Q · filed 2024-05-08 | -$131.00M derived: sum of 2 quarters · filed 2025-02-25 | -$168.00M derived: sum of 3 quarters · filed 2025-02-25 | -$205.00M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | -$76.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$113.00M derived: sum of 2 quarters · filed 2025-02-25 | -$150.00M derived: sum of 3 quarters · filed 2025-02-25 | -$179.00M 10-K · filed 2025-02-25 | |||
| 2022-09-30 | -$37.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$74.00M derived: sum of 2 quarters · filed 2023-11-07 | -$103.00M 10-Q · filed 2023-11-07 | -$177.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-06-30 | -$37.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$66.00M 10-Q · filed 2023-08-07 | -$140.00M derived: sum of 3 quarters · filed 2024-02-26 | -$581.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2022-03-31 | -$29.00M 10-Q · filed 2023-05-09 | -$103.00M derived: sum of 2 quarters · filed 2024-02-26 | -$544.00M derived: sum of 3 quarters · filed 2024-02-26 | -$569.00M derived: sum of 4 quarters · filed 2024-02-26 | |||
| 2021-12-31 | -$74.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | -$515.00M derived: sum of 2 quarters · filed 2024-02-26 | -$540.00M derived: sum of 3 quarters · filed 2024-02-26 | -$530.00M 10-K · filed 2024-02-26 | |||
| 2021-09-30 | -$441.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$466.00M derived: sum of 2 quarters · filed 2022-11-08 | -$456.00M 10-Q · filed 2022-11-08 | -$530.00M derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-06-30 | -$25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$15.00M 10-Q · filed 2022-08-08 | -$89.00M derived: sum of 3 quarters · filed 2023-03-01 | -$4.79B derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $10.00M 10-Q · filed 2022-05-09 | -$64.00M derived: sum of 2 quarters · filed 2023-03-01 | -$4.76B derived: sum of 3 quarters · filed 2023-03-01 | -$4.75B derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$74.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$4.77B derived: sum of 2 quarters · filed 2023-03-01 | -$4.76B derived: sum of 3 quarters · filed 2023-03-01 | -$4.78B 10-K · filed 2023-03-01 | -$4.78B 10-K · filed 2021-03-01 | ||
| 2020-09-30 | -$4.70B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$4.68B derived: sum of 2 quarters · filed 2021-11-05 | -$4.71B 10-Q · filed 2021-11-05 | -$4.71B 10-Q · filed 2020-11-06 | -$4.78B derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$9.00M 10-Q · filed 2021-08-09 | -$83.50M derived: sum of 3 quarters · filed 2022-02-28 | -$166.50M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | -$20.00M 10-Q · filed 2021-05-07 | -$19.60M 10-Q · filed 2020-05-07 | -$94.50M derived: sum of 2 quarters · filed 2022-02-28 | -$177.50M derived: sum of 3 quarters · filed 2022-02-28 | -$224.00M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | -$74.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$157.50M derived: sum of 2 quarters · filed 2022-02-28 | -$204.00M derived: sum of 3 quarters · filed 2022-02-28 | -$235.00M 10-K · filed 2022-02-28 | -$234.80M 10-K · filed 2020-02-28 | ||
| 2019-09-30 | -$83.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$129.50M derived: sum of 2 quarters · filed 2020-11-06 | -$160.50M 10-Q · filed 2020-11-06 | -$208.60M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-06-30 | -$46.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$77.50M 10-Q · filed 2020-07-30 | -$125.60M derived: sum of 3 quarters · filed 2021-03-01 | -$147.00M derived: sum of 4 quarters · filed 2021-03-01 | |||
| 2019-03-31 | -$31.00M 10-Q · filed 2020-05-07 | -$28.50M 10-Q · filed 2019-05-14 | -$79.10M derived: sum of 2 quarters · filed 2021-03-01 | -$100.50M derived: sum of 3 quarters · filed 2021-03-01 | -$123.60M derived: sum of 4 quarters · filed 2021-03-01 | ||
| 2018-12-31 | -$48.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$69.50M derived: sum of 2 quarters · filed 2021-03-01 | -$92.60M derived: sum of 3 quarters · filed 2021-03-01 | -$127.00M 10-K · filed 2021-03-01 | |||
| 2018-09-30 | -$21.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$44.50M derived: sum of 2 quarters · filed 2019-11-08 | -$78.90M 10-Q · filed 2019-11-08 | -$114.40M derived: sum of 4 quarters · filed 2020-02-28 | |||
| 2018-06-30 | -$23.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | -$57.50M 10-Q · filed 2019-08-13 | -$93.00M derived: sum of 3 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | -$34.40M 10-Q · filed 2019-05-14 | -$69.90M derived: sum of 2 quarters · filed 2020-02-28 | |||||
| 2017-12-31 | -$35.50M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | -$964.60M 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | -$929.10M 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | -$182.10M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |